Brief: Arcutis Biotherapeutics Q4 basic EPS USD -0.72
27/02/2024 10:53
Feb 27 (Reuters) - Arcutis Biotherapeutics Q4 basic EPS USD -0.72 vs. IBES estimate USD -0.78. * Q4 net income USD -66.284 million * Q4 operating income USD -61.169 million vs. IBES estimate USD -68.7 million * Q4 product revenue USD 13.526 million * Q4 operating expenses USD 74.695 million
Recent news on Arcutis Biotherapeutics
See all newsBrief: Arcutis Biotherapeutics reports inducement grants under Nasdaq listing rule 5635(C)(4
Arcutis Q1 product revenue rises 65% yr/yr, net loss narrows
Brief: Arcutis Announces Promotion Of MAS Matsuda To Executive Vice President And Chief Legal Officer To Support Next Phase Of Growth
Brief: Arcutis Begins Enrolling Phase 1A/1B Study Evaluating Arq-234, A Cd200r Agonist, In Healthy Volunteers And Adults With Atopic Dermatitis
Brief: Arcutis Biotherapeutics Inc Files For Mixed Shelf